デフォルト表紙
市場調査レポート
商品コード
1612742

がんバイオマーカー市場:バイオマーカータイプ別、がんタイプ別、技術別、用途別、エンドユーザー別-2025~2030年の世界予測

Cancer Biomarkers Market by Biomarker Type (Genetic, Protein), Cancer Type (Blood Cancer, Breast Cancer, Colorectal Cancer), Technology, Application, End User - Global Forecast 2025-2030


出版日
発行
360iResearch
ページ情報
英文 183 Pages
納期
即日から翌営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=152.30円
がんバイオマーカー市場:バイオマーカータイプ別、がんタイプ別、技術別、用途別、エンドユーザー別-2025~2030年の世界予測
出版日: 2024年12月01日
発行: 360iResearch
ページ情報: 英文 183 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

がんバイオマーカー市場は、2023年に283億1,000万米ドルと評価され、2024年には312億3,000万米ドルに達すると予測され、CAGR 10.71%で成長し、2030年には577億5,000万米ドルに達すると予測されています。

がんバイオマーカーとは、血液、その他の体液、組織中に存在し、がんの存在を示す生体分子のことです。その範囲には、検出、診断、予後、治療モニタリングが含まれ、個別化医療において重要です。がんバイオマーカー研究は、早期発見、より正確な診断、患者の転帰を改善するオーダーメイド治療に不可欠です。バイオマーカーは、臨床診断、創薬研究開発、がん研究、放射線医学、病理学などに幅広く応用されています。最終用途は、病院、研究所、診断センター、バイオテクノロジーや製薬会社など多岐にわたる。主な成長要因としては、がん罹患率の上昇、がんゲノム研究への資金提供の増加、オミックス技術の技術的進歩、非侵襲的検査手順への需要の高まりなどが挙げられます。新規バイオマーカーを発見する可能性のあるプロテオミクス、ゲノミクス、バイオインフォマティクスの進歩や、ヘルスケア・インフラが急速に改善しつつある新興市場に潜在的なビジネスチャンスがあります。しかし、バイオマーカー探索と検証にかかる高コスト、規制の複雑さ、結果の解釈に影響を及ぼすバイオマーカー発現のばらつきといった課題に直面しています。これらを克服するには、ビッグデータ解析と人工知能を活用して予測精度を高め、マルチオミクスデータを統合してより正確なマーカーを発見することが重要です。イノベーションに最適な分野としては、リキッドバイオプシー技術の開発、マイクロRNAやエクソソームを用いたバイオマーカーの探索、ポイントオブケア検査機能の向上などが挙げられます。学術機関、ヘルスケアプロバイダー、バイオテクノロジー企業のコラボレーションは、イノベーションを加速し、新たなソリューションを市場にもたらすことができます。がんバイオマーカー市場は、急速な技術進化と、がんの早期発見と個別化治療という差し迫った要求を満たすための絶え間ない技術革新の推進を特徴とする、非常にダイナミックで競争の激しい市場です。次世代シーケンシング(NGS)技術の採用や、データ解析における人工知能のような統合的アプローチの探求は、競争優位性をもたらす可能性があります。

主な市場の統計
基準年[2023] 283億1,000万米ドル
推定年[2024] 312億3,000万米ドル
予測年[2030] 577億5,000万米ドル
CAGR(%) 10.71%

市場力学:急速に進化するがんバイオマーカー市場の主要市場インサイトを公開

がんバイオマーカー市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

  • 市場促進要因
    • 人口におけるがん疾患の有病率の増加
    • がん早期発見のための取り組みや啓発キャンペーンの増加
    • 医療インフラとヘルスケア支出の増加
  • 市場抑制要因
    • 研究開発に伴う高コスト
  • 市場機会
    • 侵攻性肝がんを検出するための優れたバイオマーカーの出現
    • 肺がん早期発見のための新規バイオマーカー導入に向けた活発な研究活動
  • 市場の課題
    • 複雑で厳しい規制

ポーターのファイブフォース:がんバイオマーカー市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析:がんバイオマーカー市場における外部からの影響の把握

外部マクロ環境要因は、がんバイオマーカー市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析がんバイオマーカー市場における競合情勢の把握

がんバイオマーカー市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスがんバイオマーカー市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、がんバイオマーカー市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨がんバイオマーカー市場における成功への道筋を描く

がんバイオマーカー市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています:

1.市場の浸透度:現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度:新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化:最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報:競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション:将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています:

1.現在の市場規模と今後の成長予測は?

2.最高の投資機会を提供する製品、セグメント、地域はどこか?

3.市場を形成する主な技術動向と規制の影響とは?

4.主要ベンダーの市場シェアと競合ポジションは?

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 人口におけるがん疾患の罹患率の増加
      • がんの早期発見に向けた取り組みと啓発キャンペーンの増加
      • ヘルスケアインフラとヘルスケア費の拡大
    • 抑制要因
      • 研究開発にかかるコストの高さ
    • 機会
      • 悪性肝がんの検出のためのより優れたバイオマーカーの出現
      • 肺がんの早期発見のための新たなバイオマーカーの導入に向けた活発な調査活動
    • 課題
      • 複雑かつ厳格な規制遵守
  • 市場セグメンテーション分析
    • バイオマーカーの種類:血液や組織に含まれるタンパク質を通じてがんの存在を検出するタンパク質バイオマーカーの有用性
    • 応用:患者の治療結果を改善するための早期発見のための診断におけるバイオマーカーの選好
  • ポーターのファイブフォース分析
  • PESTEL分析
    • 政治的
    • 経済
    • 社交
    • 技術的
    • 法律上
    • 環境

第6章 がんバイオマーカー市場バイオマーカーの種類別

  • 遺伝的
  • タンパク質

第7章 がんバイオマーカー市場がんの種類別

  • 血液がん
  • 乳がん
  • 大腸がん
  • 肺がん
  • 卵巣がん
  • 前立腺がん
  • 皮膚がん
  • 胃がん

第8章 がんバイオマーカー市場:技術別

  • バイオインフォマティクス
  • 細胞遺伝学
  • イメージング技術
  • 免疫測定
  • オミックス技術

第9章 がんバイオマーカー市場:用途別

  • 診断
  • 医薬品の発見と開発
  • 予測
  • リスクアセスメント

第10章 がんバイオマーカー市場:エンドユーザー別

  • 学術・がん研究センター
  • 病院
  • 専門センター

第11章 南北アメリカのがんバイオマーカー市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第12章 アジア太平洋地域のがんバイオマーカー市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第13章 欧州・中東・アフリカのがんバイオマーカー市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第14章 競合情勢

  • 市場シェア分析2023
  • FPNVポジショニングマトリックス, 2023
  • 競合シナリオ分析
    • クロマコードとジョージア医科大学が戦略的提携し、NSCLC診断能力を強化
    • 次世代がん診断のためのXtalPiとCK Life SciencesのAI連携強化
    • がん治療の精度向上:FDAが腫瘍治療薬のコンパニオン診断検査を規制するパイロットプログラムを開始
  • 戦略分析と提言

企業一覧

  • Abbott Laboratories Inc.
  • Agilent Technologies, Inc.
  • ASURAGEN, INC.
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Bristol-Myers Squibb Company
  • Bruker Corporation
  • Charles River Laboratories International, Inc.
  • Enzo Biochem, Inc.
  • Epigenomics AG
  • Eurofins Scientific SE
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd.
  • GE HealthCare Technologies Inc.
  • Hologic, Inc.
  • Illumina, Inc.
  • Merck KGaA
  • Myriad Genetics, Inc.
  • PerkinElmer, Inc.
  • Pfizer Inc.
  • QIAGEN N.V
  • Quest Diagnostics Incorporated
  • Siemens Healthcare GmbH
  • Sysmex Corporation
  • Thermo Fisher Scientific Inc.
図表

LIST OF FIGURES

  • FIGURE 1. CANCER BIOMARKERS MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER BIOMARKERS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 19. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. CANCER BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 25. CANCER BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER BIOMARKERS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER BIOMARKERS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER BIOMARKERS MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY GENETIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROTEIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY OVARIAN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY SKIN CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY STOMACH CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY BIOINFORMATICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY CYTOGENETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY IMAGING TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY OMICS TECHNOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY RISK ASSESSMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY ACADEMIC & CANCER RESEARCH CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CANCER BIOMARKERS MARKET SIZE, BY SPECIALITY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES CANCER BIOMARKERS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. CHINA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 80. CHINA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. INDIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 85. INDIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. INDIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 90. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. INDONESIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. JAPAN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 95. JAPAN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. JAPAN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 100. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. MALAYSIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 105. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. PHILIPPINES CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 110. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 111. SINGAPORE CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 115. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. SOUTH KOREA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 120. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. TAIWAN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. THAILAND CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 125. THAILAND CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. THAILAND CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 129. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 130. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 131. VIETNAM CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA CANCER BIOMARKERS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. DENMARK CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 141. DENMARK CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. DENMARK CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. EGYPT CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 146. EGYPT CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 147. EGYPT CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. FINLAND CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 151. FINLAND CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. FINLAND CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. FRANCE CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 156. FRANCE CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. FRANCE CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 160. GERMANY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 161. GERMANY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. GERMANY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 166. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 167. ISRAEL CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. ITALY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 171. ITALY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 172. ITALY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 176. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. NETHERLANDS CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 180. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 181. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. NIGERIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. NORWAY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 186. NORWAY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. NORWAY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 190. POLAND CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 191. POLAND CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. POLAND CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 195. QATAR CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 196. QATAR CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 197. QATAR CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 200. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 201. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 202. RUSSIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. SAUDI ARABIA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 206. SAUDI ARABIA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 207. SAUDI ARABIA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 210. SOUTH AFRICA CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 211. SOUTH AFRICA CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 212. SOUTH AFRICA CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. SPAIN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 216. SPAIN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. SPAIN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 220. SWEDEN CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 221. SWEDEN CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 222. SWEDEN CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 225. SWITZERLAND CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 226. SWITZERLAND CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 227. SWITZERLAND CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. TURKEY CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 231. TURKEY CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 232. TURKEY CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED ARAB EMIRATES CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY BIOMARKER TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
  • TABLE 240. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 241. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 242. UNITED KINGDOM CANCER BIOMARKERS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
  • TABLE 243. CANCER BIOMARKERS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 244. CANCER BIOMARKERS MARKET, FPNV POSITIONING MATRIX, 2023
目次
Product Code: MRR-437517DB6E4D

The Cancer Biomarkers Market was valued at USD 28.31 billion in 2023, expected to reach USD 31.23 billion in 2024, and is projected to grow at a CAGR of 10.71%, to USD 57.75 billion by 2030.

Cancer biomarkers are biological molecules found in blood, other body fluids, or tissues, indicating the presence of cancer. Their scope includes detection, diagnosis, prognosis, and therapeutic monitoring, making them critical in personalized medicine. Cancer biomarker research is essential for early detection, more accurate diagnoses, and tailored treatments that improve patient outcomes. They are extensively applied in clinical diagnostics, drug discovery, and development as well as cancer research, radiology, and pathology. The end-use scope spans hospitals, research laboratories, diagnostic centers, and biotechnology and pharmaceutical companies. Key growth factors include the rising prevalence of cancer, increased funding for cancer genomics research, technological advancements in omics technologies, and growing demand for non-invasive testing procedures. Potential opportunities lie in advancements in proteomics, genomics, and bioinformatics, which may uncover novel biomarkers, and in emerging markets where healthcare infrastructure is rapidly improving. However, the market faces challenges such as high costs of biomarker discovery and validation, regulatory complexities, and variability in biomarker expression that can impact the interpretation of results. To overcome these, leveraging big data analytics and artificial intelligence to enhance predictive accuracy and integrating multi-omics data to discover more precise markers are crucial. Best areas for innovation include developing liquid biopsy technologies, exploring microRNA and exosome-based biomarkers, and improving point-of-care testing capabilities. Collaborations between academic institutions, healthcare providers, and biotech firms can accelerate innovation and bring new solutions to market. The cancer biomarker market is highly dynamic and competitive, characterized by rapid technological evolution and a constant drive for innovation to meet the pressing demands of early cancer detection and personalized treatment. Adoption of next-generation sequencing (NGS) technologies and the exploration of integrative approaches like artificial intelligence in data analysis could offer a competitive edge.

KEY MARKET STATISTICS
Base Year [2023] USD 28.31 billion
Estimated Year [2024] USD 31.23 billion
Forecast Year [2030] USD 57.75 billion
CAGR (%) 10.71%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Biomarkers Market

The Cancer Biomarkers Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of cancer disorders among population
    • Rising initiatives and awareness campaigns for early cancer detection
    • Growing healthcare infrastructure and healthcare spending
  • Market Restraints
    • High costs associated with research and development
  • Market Opportunities
    • Emergence of better biomarkers for detection of aggressive liver cancer
    • Robust research activities to introduce new biomarkers for early detection of lung cancer
  • Market Challenges
    • Complex and stringent regulatory compliances

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Biomarkers Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Biomarkers Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Biomarkers Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Biomarkers Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Biomarkers Market

A detailed market share analysis in the Cancer Biomarkers Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Biomarkers Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Biomarkers Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Biomarkers Market

A strategic analysis of the Cancer Biomarkers Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Biomarkers Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories Inc., Agilent Technologies, Inc., ASURAGEN, INC., Bio-Rad Laboratories, Inc., bioMerieux SA, Bristol-Myers Squibb Company, Bruker Corporation, Charles River Laboratories International, Inc., Enzo Biochem, Inc., Epigenomics AG, Eurofins Scientific SE, Exact Sciences Corporation, F. Hoffmann-La Roche Ltd., GE HealthCare Technologies Inc., Hologic, Inc., Illumina, Inc., Merck KGaA, Myriad Genetics, Inc., PerkinElmer, Inc., Pfizer Inc., QIAGEN N.V, Quest Diagnostics Incorporated, Siemens Healthcare GmbH, Sysmex Corporation, and Thermo Fisher Scientific Inc..

Market Segmentation & Coverage

This research report categorizes the Cancer Biomarkers Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Biomarker Type, market is studied across Genetic and Protein.
  • Based on Cancer Type, market is studied across Blood Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, Ovarian Cancer, Prostate Cancer, Skin Cancer, and Stomach Cancer.
  • Based on Technology, market is studied across Bioinformatics, Cytogenetics, Imaging Technology, Immunoassays, and OMICS Technology.
  • Based on Application, market is studied across Diagnostics, Drug Discovery & Development, Prognostics, and Risk Assessment.
  • Based on End User, market is studied across Academic & Cancer Research Centers, Hospitals, and Speciality Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of cancer disorders among population
      • 5.1.1.2. Rising initiatives and awareness campaigns for early cancer detection
      • 5.1.1.3. Growing healthcare infrastructure and healthcare spending
    • 5.1.2. Restraints
      • 5.1.2.1. High costs associated with research and development
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of better biomarkers for detection of aggressive liver cancer
      • 5.1.3.2. Robust research activities to introduce new biomarkers for early detection of lung cancer
    • 5.1.4. Challenges
      • 5.1.4.1. Complex and stringent regulatory compliances
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Biomarker Type: Usability of protein biomarkers in detecting the presence of cancer through proteins found in blood or tissue
    • 5.2.2. Application: Preferences for biomarkers in diagnostic for early-stage detection to improve treatment outcomes for patients
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer Biomarkers Market, by Biomarker Type

  • 6.1. Introduction
  • 6.2. Genetic
  • 6.3. Protein

7. Cancer Biomarkers Market, by Cancer Type

  • 7.1. Introduction
  • 7.2. Blood Cancer
  • 7.3. Breast Cancer
  • 7.4. Colorectal Cancer
  • 7.5. Lung Cancer
  • 7.6. Ovarian Cancer
  • 7.7. Prostate Cancer
  • 7.8. Skin Cancer
  • 7.9. Stomach Cancer

8. Cancer Biomarkers Market, by Technology

  • 8.1. Introduction
  • 8.2. Bioinformatics
  • 8.3. Cytogenetics
  • 8.4. Imaging Technology
  • 8.5. Immunoassays
  • 8.6. OMICS Technology

9. Cancer Biomarkers Market, by Application

  • 9.1. Introduction
  • 9.2. Diagnostics
  • 9.3. Drug Discovery & Development
  • 9.4. Prognostics
  • 9.5. Risk Assessment

10. Cancer Biomarkers Market, by End User

  • 10.1. Introduction
  • 10.2. Academic & Cancer Research Centers
  • 10.3. Hospitals
  • 10.4. Speciality Centers

11. Americas Cancer Biomarkers Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Cancer Biomarkers Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Cancer Biomarkers Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Strategic Collaboration between ChromaCode and Medical College of Georgia to Enhance NSCLC Diagnostic Capabilities
    • 14.3.2. Enhanced AI Collaboration Between XtalPi and CK Life Sciences for Next-Generation Cancer Diagnostics
    • 14.3.3. Enhancing Precision in Cancer Treatment: FDA Initiates Pilot Program to Regulate Companion Diagnostic Tests for Oncology Drugs
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories Inc.
  • 2. Agilent Technologies, Inc.
  • 3. ASURAGEN, INC.
  • 4. Bio-Rad Laboratories, Inc.
  • 5. bioMerieux SA
  • 6. Bristol-Myers Squibb Company
  • 7. Bruker Corporation
  • 8. Charles River Laboratories International, Inc.
  • 9. Enzo Biochem, Inc.
  • 10. Epigenomics AG
  • 11. Eurofins Scientific SE
  • 12. Exact Sciences Corporation
  • 13. F. Hoffmann-La Roche Ltd.
  • 14. GE HealthCare Technologies Inc.
  • 15. Hologic, Inc.
  • 16. Illumina, Inc.
  • 17. Merck KGaA
  • 18. Myriad Genetics, Inc.
  • 19. PerkinElmer, Inc.
  • 20. Pfizer Inc.
  • 21. QIAGEN N.V
  • 22. Quest Diagnostics Incorporated
  • 23. Siemens Healthcare GmbH
  • 24. Sysmex Corporation
  • 25. Thermo Fisher Scientific Inc.